The Effect of Puncture Sites of Portal Vein in TIPS with ePTFE-Covered Stents on Postoperative Long-Term Clinical Efficacy

Table 4

The results of the univariate analyses.

Variables	Shunt patency			HE			Survival
	HR	95% CI	value	HR	95% CI	value	HR	95% CI	value
Gender (M/F)	1.59	1.10–2.37	0.032	1.02	0.82–1.41	NS	1.31	0.82–2.05	NS
Age (y)	0.89	0.95–1.02	NS	1.04	1.02–1.06	<0.001	1.02	0.98–1.05	NS
Main preoperative symptoms (bleeding/ascites)	0.72	0.48–1.12	NS	1.27	0.78–2.04	NS	1.65	1.12–2.54	0.039
Previous ascites (yes/no)	0.89	0.65–1.43	NS	1.65	1.14–2.41	0.021	2.42	1.58–3.76	0.002
Previous HE (yes/no)	0.95	0.71–1.54	NS	1.74	1.22–2.60	0.016	0.71	0.46–1.12	NS
Platelet count (×10^9/L)	1.01	0.98–1.03	NS	1.01	0.99–1.02	NS	0.99	0.99–1.0	0.025
Serum albumin (g/L)	0.96	0.94–1.02	NS	0.97	0.94–0.99	0.021	0.95	0.91–0.98	0.032
Serum bilirubin (mmol/L)	1.00	0.98–1.01	NS	1.00	0.99–1.01	NS	1.01	1.00-1.02	0.012
INR	0.84	0.51–1.43	NS	2.19	1.20–3.74	0.010	3.02	1.76–5.09	<0.001
Child-Pugh score	1.05	0.91–1.15	NS	1.37	1.26–1.49	0.006	1.49	1.35–1.65	<0.001
MELD score	0.97	0.90–1.03	NS	1.28	1.17–1.41	0.021	1.09	1.04–1.14	0.005
Reduction ratio of PSG (%)	0.99	0.98–1.01	NS	1.04	1.02–1.06	0.007	1.01	0.99–1.02	NS
Stent diameter (6/8 mm)	2.04	1.52–3.15	<0.001	1.97	1.56–2.58	< 0.001	0.80	0.54–1.20	NS
Puncture site of portal vein (bifurcation/right/left)	1.84	1.54–2.21	0.012	2.30	1.62–3.28	<0.001	1.75	1.32–2.42	0.004

HE: hepatic encephalopathy; INR: international normalized ratio; MELD: model for end-stage liver diseases; NS: nonsignificant; PSG: portosystemic pressure gradient.